Get the Stockscreener App
12.42
5.77%
-0.76
Pre-market:
12.42
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis director Howard G. Welgus sells $127,100 in common stock - MSN
Arcutis Biotherapeutics executive sells shares worth $153,873 - MSN
Arcutis Biotherapeutics exec sells $27,597 in stock - MSN
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - MarketBeat
Masaru Matsuda Sells 8,338 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Strengthens Team with Strategic RSU Grants Worth MillionsKey Details Revealed - StockTitan
Arcutis Biotherapeutics' senior VP Matsuda sells $105,892 in stock - MSN
Arcutis director Howard G. Welgus sells $127,100 in common stock By Investing.com - Investing.com South Africa
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus.com
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares By Investing.com - Investing.com Canada
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin" - Nasdaq
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short Interest - MarketBeat
Jennison Associates LLC Raises Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Recent 4.4% pullback isn't enough to hurt long-term Arcutis Biotherapeutics (NASDAQ:ARQT) shareholders, they're still up 118% over 1 year - Simply Wall St
(ARQT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 6.8%Should You Buy? - MarketBeat
Arcutis Biotherapeutics to Present at Guggenheim SMID Cap Biotech Conference - StockTitan
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Zweig DiMenna Associates LLC Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period (ARQT) - Seeking Alpha
Objective long/short (ARQT) Report - Stock Traders Daily
HC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3% - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4%Time to Sell? - MarketBeat
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade - MSN
Arcutis Biotherapeutics’ (ARQT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Arcutis stock target lifted, buy rating held on significant developments By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap UpStill a Buy? - MarketBeat
Arcutis stock target lifted, buy rating held on significant developments - Investing.com India
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews - Benzinga
JPMorgan Chase & Co. Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Shares Climb on Strong Product Revenue Estimates - MarketWatch
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Biotech Stocks Facing FDA Decision In July 2024 - RTTNews
Arcutis Biotherapeutics, Inc. Announces Preliminary Unaudited Earnings Guidance for Fourth Quarter and Full Year 2024 - Marketscreener.com
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million - The Manila Times
Arcutis Q4 Revenue Surges 366% to $63M as ZORYVE Demand Accelerates Across Indications - StockTitan
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer -June 01, 2021 at 07:30 am EDT - Marketscreener.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%Here's What Happened - MarketBeat
Commit To Purchase Arcutis Biotherapeutics At $7.50, Earn 21.3% Using Options - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says - Defense World
When the Price of (ARQT) Talks, People Listen - Stock Traders Daily
Mizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):